Cantor Fitzgerald initiated coverage on Stratasys with a new price target
$SSYS
Computer peripheral equipment
Technology
Cantor Fitzgerald initiated coverage of Stratasys with a rating of Overweight and set a new price target of $24.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/13/2024 | $24.00 | Overweight | Cantor Fitzgerald |
| 1/4/2023 | $15.00 | Hold → Buy | Needham |
| 11/8/2022 | Underperform → Mkt Perform | William Blair | |
| 8/17/2022 | $24.00 | Outperform | Credit Suisse |
| 5/17/2022 | $25.00 → $23.00 | Underweight → Neutral | JP Morgan |
| 2/24/2022 | $30.00 | Hold → Buy | Cross Research |
| 11/4/2021 | Neutral → Underweight | JP Morgan | |
| 11/4/2021 | Overweight → Neutral | JP Morgan |
Transaction at a Premium Underscores Leading Position in the Additive Manufacturing Industry and Positions Stratasys to Drive Growth Strengthens Balance Sheet to Capture Market Opportunities Fortissimo's Founding and Managing Partner, Yuval Cohen, to Join the Stratasys Board Stratasys Ltd. (NASDAQ:SSYS) ("Stratasys" or the "Company"), a leader in polymer 3D printing solutions, today announced that Fortissimo Capital ("Fortissimo"), a leading Israeli private equity fund investing in technology and industrials, has entered into an agreement to invest $120 million in the Company, acquiring approximately 14% of Stratasys' issued and outstanding ordinary shares through a direct purchase of
Stratasys highlights achievements in environmental, social, and governance initiatives, cementing its position as a supplier of choice for sustainable AM-enabled production solutions. Stratasys Ltd. (NASDAQ:SSYS) today announced the publication of its third Mindful Manufacturing™ ESG (Environment, Social, and Governance) and Sustainability Report. Prepared in accordance with the Global Reporting Initiative (GRI) and referencing SASB (Sustainability Accounting Standards Board) standards, the report underscores Stratasys' commitment to ESG excellence and enterprise risk management through best-in-class corporate governance, a people-first approach, meaningful social impact, and robust envir
Medical facilities and device manufacturers previously limited by constraints can now create patient-specific models to enhance surgical preparation, elevate patient outcomes, and fast-track innovation Stratasys Ltd. (NASDAQ:SSYS) today announced the launch of its J5™ Digital Anatomy™ 3D printer, the latest innovation designed to address the growing demand for cost-effective, high-fidelity anatomical models. This Stratasys innovation is designed to enable hospitals, medical device manufacturers and research institutions to enhance patient outcomes, streamline operations and bring products to market faster. This press release features multimedia. View the full release here: https://www.bu
CollPlant announces six-month study data from its regenerative breast implant program, which could provide a revolutionary alternative to women for aesthetic or medical purposes and aims to address a $3 billion market opportunity Recently received a $2 million development payment from AbbVie Conference call to be held today at 10:00 a.m. U.S. EDT REHOVOT, Israel, March 26, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ:CLGN), or "CollPlant", a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced its 2024 financial results and provided a corp
Fourth quarter revenue of $150.4 million, compared to $156.3 million in the prior year period Fourth quarter GAAP net loss of $41.9 million, or $0.59 per diluted share, which includes $30.1 million non-cash impairment of an equity investment Fourth quarter Non-GAAP net income of $8.5 million, or $0.12 per diluted share Full year revenue of $572.5 million, compared to $627.6 million in 2023 Full year GAAP net loss of $120.3 million, or $1.70 per diluted share, and non-GAAP net income of $4.2 million, or $0.06 per diluted share Fourth quarter positive operating cash flow of $7.4 million Full year positive operating cash flow of $7.8 million, resulting in $150.7 million cash equiv
Schedules Fourth Quarter 2024 Conference Call for 8:30 a.m. ET on Wednesday, March 5, 2025 Stratasys Ltd. (NASDAQ:SSYS) ("Stratasys" or the "Company"), a leader in polymer 3D printing solutions, today announced unaudited preliminary approximate financial results for the fourth quarter 2024. Preliminary Fourth Quarter 2024 Results Revenue of $150.1 to $150.5 million, with hardware sequentially higher and consumables sequentially lower compared to the third quarter of 2024 GAAP gross margin of 46.0% to 46.5%, non-GAAP gross margin of 49.4% to 49.7%. GAAP operating loss of $13.3 to $14.4 million, non-GAAP operating income of $9.0 to $9.5 million GAAP net loss of $15.3 to $16.5
S-8 - STRATASYS LTD. (0001517396) (Filer)
20-F - STRATASYS LTD. (0001517396) (Filer)
6-K - STRATASYS LTD. (0001517396) (Filer)
Cantor Fitzgerald initiated coverage of Stratasys with a rating of Overweight and set a new price target of $24.00
Needham upgraded Stratasys from Hold to Buy and set a new price target of $15.00
William Blair upgraded Stratasys from Underperform to Mkt Perform
SC 13G/A - STRATASYS LTD. (0001517396) (Subject)
SC 13G/A - STRATASYS LTD. (0001517396) (Subject)
SC 13G/A - STRATASYS LTD. (0001517396) (Subject)
Launch of AIS Antero Materials, developed in collaboration with Boeing, Blue Origin, Northrop Grumman, U.S. Naval Air Systems Command, the U.S. Air Force, Raytheon Technologies, and the National Institute for Aviation Research, represents significant progress in scaling adoption of additive manufacturing for high-performance applications in highly regulated industries Stratasys Ltd. (NASDAQ:SSYS) today announced the launch of AIS™ Antero® 800NA and AIS™ Antero 840CN03 as validated materials for the Stratasys F900®, marking a new milestone in qualified additive manufacturing for aerospace, defense, and other highly regulated industries. These new AIS™ advanced industrial solution materials
CollPlant announces six-month study data from its regenerative breast implant program, which could provide a revolutionary alternative to women for aesthetic or medical purposes and aims to address a $3 billion market opportunity Recently received a $2 million development payment from AbbVie Conference call to be held today at 10:00 a.m. U.S. EDT REHOVOT, Israel, March 26, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ:CLGN), or "CollPlant", a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced its 2024 financial results and provided a corp
New Dental Partnerships Underscore Growing Demand for Stratasys' Industry-Leading 3D Printing Solutions Stratasys Ltd. (NASDAQ:SSYS), today announced new strategic partnerships with Spain-based Nueva Galimplant, along with Germany-based Gold Quadrat and Metaux Precieux to offer Stratasys' comprehensive suite of dental 3D printing solutions, including TrueDent™ monolithic, full-color digital dentures. These partnerships expand the availability of Stratasys' dental offering in Europe, reinforcing the company's commitment to delivering advanced, scalable 3D printing solutions that reduce labor time and costs for dental laboratories. This press release features multimedia. View the full releas